Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015)
Alnylam Pharmaceuticals (ALNY) posted Curent Deferred Tax Liability of $9.4 million for Q3 2015, down 52.14% on a QoQ basis from $19.7 million in Q2 2015.
Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015) Analysis & Trends
Alnylam Pharmaceuticals' Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $9.4 million for Q3 2015.
- Quarterly Curent Deferred Tax Liability changed N/A year-over-year to $9.4 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $9.4 million (changed N/A YoY) and the FY2014 annual result came in at $31.7 million, changed N/A from the prior year.
- Curent Deferred Tax Liability was $9.4 million for Q3 2015 at Alnylam Pharmaceuticals, down from $19.7 million in the prior quarter.
- Across five years, Curent Deferred Tax Liability topped out at $33.7 million in Q1 2015 and bottomed at $9.4 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 9.41 Mn |
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |
| Dec 31, 2014 | 31.67 Mn |